EDITORIAL article
Front. Med.
Sec. Family Medicine and Primary Care
This article is part of the Research TopicPioneers & Pathfinders: 10 Years of Frontiers in MedicineView all 19 articles
Editorial: Pioneers & Pathfinders: 10 Years of Frontiers in Medicine
Provisionally accepted- 1Institute for Interdisciplinary Innovation in healthcare, Université libre de Bruxelles, Institut pour l'Innovation Interdisciplinaire en Santé, Université Libre de Bruxelles, Brussels, Belgium
- 2National Institutes of Health National Cancer Institute, Bethesda, United States
- 3The University of Sydney, Sydney, Australia
- 4Lomonosov Moscow State University, Moscow, Russia
- 5Min Sheng General Hospital, Taoyuan District, Taiwan
- 6Universidade de Lisboa, Lisbon, Portugal
- 7Aristoteleio Panepistemio Thessalonikes, Thessaloniki, Greece
- 8University of Alberta, Edmonton, Canada
- 9University of Pittsburgh School of Medicine, Pittsburgh, United States
- 10Universidad de Zaragoza, Zaragoza, Spain
- 11University of Florida, Gainesville, United States
- 12Universite de Lausanne, Lausanne, Switzerland
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
As Frontiers in Medicine celebrates its 10th anniversary as a journal in the top 25% of its category, we invited authors to submit papers reporting what they considered as meaningful advances, worth publishing in different sections of the journal as part of this research topic. Based on the contributions received and the input of our section editors, we mention here below key developments in different medical disciplines -emphasizing the growing impact of artificial intelligence (AI). Indeed, the paper by Mian et al. highlighted the explosive growth of artificial intelligence (AI) in healthcare, documenting over 1,800 publications from 97 countries between 2019 and 2023 in their bibliometric analysis of AI in medicine. Their study identified key progress areas, emerging fields, and leading contributors-including prominent countries, institutions, and researchers-providing valuable insights into current collaborative frameworks and potential future research directions (1). Among the many domains where AI is making an impact, precision oncology exemplifies its transformative potential, enabling more personalized cancer care through enhanced diagnostic accuracy, Hasham and Sultan have emphasized its growing impact in pediatric oncology, where AI-driven innovations hold promise for improving diagnosis and tailoring therapies for young patients (2). Despite these promising advances, the field remains in its infancy, and significant implementation challenges persist. While the success of AI in precision medicine underscores its ability to address complex medical problems, access to advanced tools remains confined to wellresourced healthcare systems. Moving forward, sustained progress will depend on the establishment of rigorous methodological standards, robust ethical frameworks, and the integration of real-world data with the goal of benefiting all global population. As part of this research topic, the current and anticipated contributions of AI are also discussed in dermatology (3), gastroenterology (4), and intensive care/anesthesiology (5), nephrology (6,7) and rheumatology (8,9). Clearly, regulatory science and public health (10) will also benefit from AI developments. In this new era, it will be essential to maintain public trust in the recommendations made by experts, taking into consideration that the opinions expressed might be conflicting and influenced by political considerations (11).Furthermore, the tremendous potential of analytical techniques for deciphering genotypephenotype relationship has been emphasized by Victoria Bunik (12). She underlines that the field requires development of public databases on genetic variety and associated disease diagnostics, as well as specific programs in medical education.Several other themes are covered in this research topic, including new applications of radiopharmaceuticals in oncology and autoimmune diseases (13,14) as well as new targeted therapeutic modalities in hematology (15,16). We also received an important contribution on the impact of education of healthcare professions with a focus on emotional intelligence (17).We warmly hope that the value of this series of articles will be recognized and incentivize new submissions to our journal which is now established as a flagship among open access medical publications.
Keywords: artificial intelligence, precision medicine, pharmaceuticals, innovation, Public trust
Received: 31 Oct 2025; Accepted: 04 Nov 2025.
Copyright: © 2025 Goldman, Chen, Bloomfield, Bunik, Chao, Fonseca, Gavriilaki, Gniadecki, Kaynar, Lanas, Lima, Mainous, Monrouxe and Treglia. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Michel Goldman, mgoldman@ulb.ac.be
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.